Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA.

ABSTRACT:

Background

The introduction of oral direct-acting antivirals (DAAs) has dramatically changed the landscape of HCV treatment. However, a small percentage of patients fail to achieve sustained virologic response (SVR). Understanding the number of people who fail on DAAs and require re-treatment is important for budget impact and disease burden projections.

Aim

To quantify the number of HCV patients who fail to achieve SVR on oral DAAs (NS5A vs. non-NS5A) and require re-treatment.

Methods

We used a mathematical model to simulate clinical management of HCV in the USA, which included the implementation of HCV screening, treatment, and disease progression. We simulated different waves of DAA treatment and used real-world data to extract SVR rates and market shares of availa

SUBMITTER: Chhatwal J 

PROVIDER: S-EPMC5842132 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature